ArticleIn silico pharmacology2025
Single-cell RNA seq data analysis reveals molecular markers and possible treatment targets for laryngeal squamous cell carcinoma (LSCC): an in-silico approach.
Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Laryngeal squamous cell carcinoma (LSCC), a complex cancer driven by genetic mutations, poses significant challenges for detection and treatment. Single-cell RNA sequencing (scRNA-seq) has emerged as a promising tool to uncover the cellular heterogeneity in cancer and identify novel therapeutic targets. In this study, we used scRNA-seq data (GSE252490) to explore molecular biomarkers for LSCC diagnosis and treatment. After processing and standardizing the data, we performed principal component analysis to identify highly variable genes. Cell clustering revealed 12 distinct clusters with unique molecular features. Differential gene expression analysis identified 6434 differentially expressed genes (DEGs), which were further analyzed using gene ontology enrichment to explore biological processes involved in LSCC progression. Protein-protein interaction (PPI) network analysis revealed 20 central genes associated with key cancer pathways. Pathway enrichment analysis through KEGG highlighted the involvement of these genes in various cancer-related pathways. Notably, genes such as CCL3, EPCAM, and IL8, with elevated expression, were linked to survival outcomes in LSCC. This comprehensive analysis provides valuable insights into the molecular landscape of LSCC, identifying potential biomarkers and therapeutic targets for improved diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.